Figure 1 Gut microorganisms at the intersection of several diseases

Slides:

Advertisements

Similar presentations

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Advertisements

Figure 2 Exosome composition

Figure 4 The gut microbiota directly influences T-cell differentiation

promotes the oncogenic activity of CagA

Figure 5 Dendritic cells in liver inflammation

Figure 1 Contribution of the gut microbiota

Figure 5 Therapeutic paradigms for interfering with the brain–gut axis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 7 Treatment algorithm for perianal fistulizing disease

Figure 6 Injection of mesenchymal stem cells in perianal fistulas

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 The microbiome–gut–brain axis

Figure 3 The T-cell cytokine tree in IBD

Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 Exosomes for delivery of RNA interference therapeutics

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Outline of the pathogenesis and overlap

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 The 'leaky gut' hypothesis

Figure 2 Effect of PPIs on gastric physiology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Schematic outlining the results of Buffington et al.

Figure 6 Combination therapy for HCC

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Figure 1 Definition and concept of ACLF

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Host range of hepatitis E virus

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 Intestinal lymph draining pattern and contents

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 An overview of the TIMER microbiota–host

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

to the liver and promote patient-derived xenograft tumour growth

Figure 7 Example colonic high-resolution manometry

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Serotonin influences many peripheral tissues

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Figure 5 Chrononutrition in the liver

Figure 2 Key brain–immune–gut interactions

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Pro-inflammatory and anti-inflammatory effects of the gut microbiota Figure 2 | Pro-inflammatory and anti-inflammatory effects of the gut microbiota.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Strategies to improve liver regeneration

Figure 1 Brain–gut axis Brain–gut axis. Schematic of the brain–gut axis, including inputs from the gut microbiota, the ENS, the immune system and the external.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 New therapeutic approaches in IBD with their specific targets

Figure 4 Local species pools that contribute to the

Figure 1 Cancer stem cell plasticity and stem cell homeostasis in the gut Figure 1 | Cancer stem cell plasticity and stem cell homeostasis in the gut.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 New therapeutic approaches in IBD therapy based on blockade of T-cell homing and retention Figure 1 | New therapeutic approaches in IBD therapy.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Figure 1 NAFLD pathogenesis

Figure 1 Colonic inflammation in IBD and link to the gut microbiota

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 The spread of colorectal cancer metastases

Presentation transcript:

Figure 1 Gut microorganisms at the intersection of several diseases Figure 1 | Gut microorganisms at the intersection of several diseases. Gut microbiota composition and activity are under the influence of numerous factors (e.g. lifestyle and host metabolic activities). In numerous studies, the gut microbiota were found to be affected in a vast number of pathological situations. Whether the complex gearing of the gut microbiota and other cell types and organs are influencing each other is still debated. Deciphering the number and respective effect of each 'cog' on the overall human metabolism might lead to novel therapeutics, and overall host physiology could be considered a gearing with every cell type potentially able to influence another. Cani, P. D. (2017) Gut microbiota — at the intersection of everything? Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.54